Drug Trial Radar · NCT07904845
A Study of BON-C1393 in Adults With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Nov 23, 2026
Primary completion
Feb 27, 2029
Study completion Feb 27, 2029
Sponsor
- Lead sponsor
- BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- First posted
- Oct 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BON-C1393 monotherapy or in combination with other anticancer regimens in adults with selected advanced solid tumors. The study will consist of Phase 1a (Dose Escalation and Dose Exploration) and Phase 1b (Dose Expansion).
Conditions
- Solid Tumors
- Advanced Solid Tumors
Interventions
BON-C1393Drug
Administered intravenously
BevacizumabDrug
Administered intravenously
CapecitabineDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1a: Number of Participants with Dose-Limiting Toxicities (DLTs)Time frame: Approximately 1 month
- Phase 1a: Number of Participants with Treatment-emergent Adverse Events (TEAEs), Treatment-related Adverse Events (TRAEs), and Serious Adverse Events (SAEs)Time frame: Up to approximately 9 months
- Phase 1b: Overall Response Rate (ORR) Assessed by the InvestigatorTime frame: Up to approximately 12 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.